Dicerna pharmaceuticals ceo
WebDicerna Pharmaceuticals, Inc. 30,350 followers on LinkedIn. Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to ... WebJun 24, 2024 · The estimated Net Worth of Douglas Fambrough is at least $17.7 Million dollars as of 15 December 2024. Douglas Fambrough owns over 13,750 units of Dicerna Pharmaceuticals Inc stock worth over $9,049,693 and over the last 9 years he sold DRNA stock worth over $3,614,546. In addition, he makes $5,048,130 as President, Chief …
Dicerna pharmaceuticals ceo
Did you know?
WebApr 4, 2024 · Aradhye, who is returning to Novartis, was most recently Executive Vice President and Chief Medical Officer at Dicerna Pharmaceuticals where he led the development of multiple clinical stage RNAi assets. ... CEO Novartis. “I would like to congratulate Marie-France, Shreeram, Steffen and Victor on their new roles, and extend …
WebNov 18, 2024 · Dicerna Pharmaceuticals Inc., a Lexington-based firm focused on ribonucleic acid interference (RNAi) drugs, has agreed to be acquired by Denmark's Novo Nordisk A/S for $3.3 billion in cash. WebAug 11, 2024 · President and CEO of Dicerna Pharmaceuticals Inc (30-Year Financial, Insider Trades) Douglas Fambrough (insider trades) bought 5,000 shares of DRNA on …
WebAs President and Chief Executive Officer at DICERNA PHARMACEUTICALS INC, Douglas M. Fambrough III, Ph.D. made $6,621,352 in total compensation. Of this total $575,000 was received as a salary, $345,000 was received as a bonus, $3,880,000 was received in stock options, $1,801,884 was awarded as stock and $19,468 came from other types of … WebRobert D. Ciappenelli is Chief Strategy Officer for Dicerna Pharmaceuticals, Inc. Mr. Ciappenelli previously held the position of Vice President-Commercial Operations at Sunovion Pharmaceuticals, Inc....
WebMay 28, 2024 · It would be hard to discount the role that CEO Douglas Fambrough has played in delivering the impressive results at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) recently. Coming up to the next AGM ...
WebFounded: 2007. Type: Company - Public (DRNA) Industry: Biotech & Pharmaceuticals. Revenue: Unknown / Non-Applicable. Competitors: Unknown. Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. globefish calgary chinookWebFeb 26, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2024 Earnings Conference Call February 25, 2024 4:30 PM ETCompany ParticipantsLauren Stival - Senior Director of IRDoug Fambrough - President and... globefish 14th streetWebAug 9, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q2 2024 Earnings Conference Call August 9, 2024 8:00 AM ETCompany ParticipantsDoug Fambrough – Chief Executive … globefish chinook mallWebNov 18, 2024 · Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform. Bagsværd, Denmark, 18 November 2024 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna).The acquisition of Dicerna’s ribonucleic acid interference … globe fire turnoutsWebFeb 28, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Lauren Stival – Stern Investor Relations, Inc. globefish calgary locationsWebCEO: Douglas M. Fambrough. Employees: 78. 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA 02140 617 621 8097. www.dicerna.com ... DICERNA PHARMACEUTICALS INC DRNA: 2024-12-28 12:45:03 UTC-0.2091: 0.2891: 250000: Current Active Short Positions. Holder Issuer Net Short Position Position Date Origin; globe firmware updateWebApr 27, 2024 · Dicerna Pharmaceuticals’ board of directors last year doubled CEO Douglas Fambrough’s paycheck for the second time as the biotech continued its deal-making spree. Fambrough earned ... globefish calgary takeout